Watch and explore
A short animated video summary of this article and an interactive version are in production and will appear here.
One number to hold on to. In a UK survey of 715 women, 31% of those with an ADHD diagnosis met criteria for provisional PMDD, compared with 10% of women without ADHD (Broughton and colleagues, British Journal of Psychiatry, 2025).
Seen by one specialty at a time? Our psychiatry and gynaecology clinic for women looks at hormones, mood, ADHD and autism together, in Harley Street or online across the UK. See the clinic or book an appointment.
What PMDD is, and how common it is
PMDD is a severe, cyclical mood condition. In the one to two weeks before a period, mood drops sharply. Women describe despair, anxiety, anger, a sense of worthlessness, brain fog and exhaustion. Within a few days of bleeding starting, they feel like themselves again. Many then spend the good fortnight repairing what the bad fortnight damaged, at work and at home.
This is what separates PMDD from ordinary premenstrual syndrome (PMS). PMS is uncomfortable. PMDD takes 10 to 14 days out of every month, and then takes much of the rest as well, because the good days are spent apologising, explaining and dealing with the consequences. By day three or four of the period the shift is over and she is back to her normal self, often bewildered by what she said and did. Then the clock starts again. Living like this for years is exhausting, and it deserves to be taken seriously.
You will often read that PMDD affects 3 to 8% of women. The best current estimate is lower and more careful. A meta-analysis of 44 studies and 50,659 women found that 1.6% of women in community samples met the full criteria when symptoms were tracked daily, and 3.2% across all studies using confirmed diagnosis (Reilly and colleagues, 2024). That is still a very large number of women.
The risk is serious. A meta-analysis found that women with PMDD had almost seven times the odds of a suicide attempt and almost four times the odds of suicidal thoughts compared with women without premenstrual disorders (Prasad and colleagues, 2021).
PMDD is also easy to miss. If the appointment falls in a good week, the woman in front of the doctor looks well. Her account of the previous fortnight can sound out of proportion to the person in the room. It is not.
Not a hormone imbalance: normal hormones, a sensitive brain
The phrase "hormone imbalance" suggests that a blood test should show something wrong. In PMDD it usually does not. Oestrogen and progesterone rise and fall in the same pattern as in women who feel well all month.
The clearest evidence comes from an experiment published in 1998. Researchers temporarily switched off the ovaries of women with severe premenstrual symptoms, and their symptoms eased. They then gave back oestradiol or progesterone. Symptoms returned in the women with premenstrual syndrome. Fifteen women without it received the same hormones and had no change in mood (Schmidt and colleagues, New England Journal of Medicine, 1998). Same hormones, different response.
PMDD symptoms sit in the two weeks after ovulation. Nothing unusual happens to the hormone curves in that window. The difference is in how the brain responds to them.
Where progesterone comes in
After ovulation, progesterone rises. The body converts part of it into a substance called allopregnanolone, which acts on the GABA system, the brain's main calming network. For most women this is settling. In PMDD the brain appears to respond to this change differently, so a signal that should calm instead unsettles.
A small trial supports this. When researchers blocked the conversion of progesterone to allopregnanolone, irritability, sadness and anxiety eased in women with PMDD, and nothing changed in women without it (Martinez and colleagues, 2016). This was a research study in 16 women, not a treatment you can ask for. It does point firmly at the brain's response and away from the hormone level.
The newest evidence looks at the receptor itself. The GABA receptor is built from several parts, called subunits, and the mix of parts decides how strongly it responds to allopregnanolone. A 2025 study compared 29 women with PMDD and 27 without across the cycle. In the symptomatic phase, the women with PMDD made less of one part, the delta subunit, which is the part most sensitive to allopregnanolone. The less of it they made, the more active the amygdala, the brain's alarm, was on a scan (Stiernman and colleagues, 2025). The receptor was measured in blood cells, not in the brain, so this is a strong clue and not proof. It suggests the PMDD brain struggles to retune its brake as hormone levels change.
We would add a note of caution. You may see confident claims online that scientists have "finally worked out" the cause, or that one brain region acts as the same switch in PMDD and ADHD. The direction of the research is clear. The fine detail is not settled.
We have written more about this in Progesterone: Friend or Foe for Mood and ADHD?
Why PMDD is more common with ADHD, and what we know about autism
ADHD
The link with ADHD is the better established of the two. In a Dutch clinic study of 209 women with ADHD, 45.5% reported symptoms consistent with PMDD (Dorani and colleagues, 2021). In the UK survey quoted above, women with an ADHD diagnosis were about three times as likely to meet criteria for provisional PMDD, and the risk was highest in women who also had anxiety or depression (Broughton and colleagues, 2025).
Two cautions. Both studies used questionnaires, not two months of daily diaries, so the true figures are likely to be lower. And many women with ADHD have premenstrual worsening of ADHD itself, which is related to PMDD but is not the same thing.
Why might the two travel together? Oestrogen supports dopamine, the chemical messenger that ADHD medication works on. When oestrogen falls before a period, attention, motivation and emotional control can all dip, and medication can feel weaker. A brain that is already sensitive to that fall may also be more sensitive to the progesterone changes described above.
Autism
Here the evidence is thinner and mixed, and we want to say so plainly.
- Obaydi and Puri, 2008: 26 autistic women with a learning disability and 36 matched women were rated daily by observers over three cycles. 92% of the autistic group met criteria for a marked premenstrual disorder, against 11%.
- Lever and Geurts, 2016: among adults in the Netherlands, about 21% of autistic women met criteria, against 3% of non autistic women.
- Groenman and colleagues, 2022: in 28 autistic and 42 non autistic women the figures were 14.3% against 9.5%, a difference that was not statistically significant.
- Groenman and colleagues, 2026: in 89 women with ADHD, 39 autistic women and 71 comparison women, provisional PMDD was raised in both the ADHD and autistic groups, with a warning that figures depend heavily on how women are recruited.
Our reading is that autistic women probably do carry more premenstrual burden, but the size of the effect is uncertain.
Why the symptoms can look different
Neurodivergent people often experience pain, bodily sensations and emotions differently. Some feel pain more intensely. Some notice it late, or find it hard to put into words. A woman may describe her premenstrual week as noise becoming unbearable, clothes hurting, or shutting down, and never use the word "mood". If the doctor is listening only for sadness, the pattern is missed.
Why a neurodivergent brain may react more strongly
Nobody has yet proved why PMDD and neurodivergence overlap. There are four plausible reasons, and we offer them as working explanations, not settled fact.
- A paradoxical response to a calming signal. Allopregnanolone normally strengthens GABA, the brain's brake. In PMDD the GABA receptors appear not to adapt smoothly as allopregnanolone rises and falls, so the result can be agitation, anxiety and irritability instead of calm (Hantsoo and Epperson, 2020).
- Less buffering to begin with. One leading theory of autism, and to a degree of ADHD, is a different balance between the brain's excitatory and calming signals. If the brake is already working hard, a monthly wobble in it may be felt as sensory overload: lights, noise and textures that were tolerable last week become too much.
- Dopamine. Hormones and their breakdown products also influence dopamine. An ADHD brain has less dopamine signalling in reserve, so the same hormonal shift can bring more fog, more distractibility and less impulse control, and can make medication feel weaker.
- The stress system. Allopregnanolone helps switch the stress response off. When that signal is unreliable, stress lasts longer. Add the daily effort of masking, and the premenstrual week can tip a woman who is coping into burnout.
These ideas fit what our patients tell us. They still need testing in studies designed for neurodivergent women, who have been left out of most hormone research.
Beyond progesterone: what else shifts before a period
Progesterone is not the whole story. Several other changes arrive in the same fortnight, and a neurodivergent brain may feel each of them more.
- Oestrogen and dopamine. Oestrogen helps the brain make dopamine and keep it working. In the first half of the cycle, rising oestrogen acts as a natural buffer for ADHD traits. When it falls before a period the buffer goes, which is why fog, exhaustion and weaker medication effect cluster in that week.
- Serotonin. Oestrogen also supports serotonin, which steadies mood and impulse control. A sharp fall can feel like a sudden loss of emotional resilience. This is one reason SSRIs help.
- Histamine. Oestrogen and histamine influence each other, and some women notice more itching, headaches, poor sleep and anxiety at certain points in the cycle. Whether histamine drives PMDD in neurodivergent women is an interesting idea that has not been properly tested, so we do not recommend antihistamines as a PMDD treatment.
- Sleep and the body clock. Many people with ADHD and autism already have a delayed body clock. Sleep often worsens in the premenstrual week, and a tired brain filters sensory input and manages emotion less well the next day.
- Polyendocrine metabolic ovarian syndrome (PMOS). Until 2026 this was called polycystic ovary syndrome (PCOS). It is more common in autistic women. In a UK study of GP records, 2.3% of autistic women had it, against 1.1% of matched women (Cherskov and colleagues, 2018). Irregular ovulation means less predictable hormone swings, which can make a premenstrual pattern harder to spot and to treat. It is one reason a gynaecology opinion is useful.
The practical message is that PMDD in a neurodivergent woman is rarely one mechanism. That is why we look at mood, attention, sleep, sensory load and the gynaecological history together.
What a calm limbic system seems to need
The limbic system, and the amygdala in particular, is the brain's alarm. Brain imaging studies suggest it is quietest when five things are true together. The common thread is steadiness. It is the swing, more than the level, that unsettles a sensitive brain.
- Oestrogen: a normal, steady level. When oestrogen is high around the middle of the cycle, the brain's stress and arousal circuits, including the amygdala, respond less to upsetting images than they do in the low oestrogen days of a period (Goldstein and colleagues, 2005).
- Progesterone and allopregnanolone: steady, not simply high. Raising allopregnanolone reduced amygdala activity and strengthened its link with the regulating frontal cortex (Sripada and colleagues, 2013). Yet a single dose of progesterone, giving levels like the second half of the cycle, increased amygdala reactivity (van Wingen and colleagues, 2008). The effect depends on dose and on the person, which is exactly the PMDD story.
- Cortisol: a well regulated daily rhythm, not a low level. Cortisol is part of how the brain switches the alarm off. In one study, hydrocortisone quietened the amygdala and later normalised its response to negative images (Henckens and colleagues, 2010). The problem is cortisol that stays raised or loses its rhythm under chronic stress.
- Testosterone: within the normal female range. Testosterone raises amygdala reactivity in women (van Wingen and colleagues, 2009), which is one reason androgen excess may matter for mood.
- Inflammation: low. Experimentally induced inflammation made the amygdala respond more strongly to threatening faces, and people felt more socially disconnected (Inagaki and colleagues, 2012).
Two cautions. These are small studies, mostly of healthy volunteers given a single dose, so they show direction and not a recipe. And there is no blood test profile that proves a calm or an overactive limbic system, so we do not order hormone panels to diagnose mood. What the research supports is the practical aim: steady hormones, good sleep, managed stress and treated inflammation or metabolic illness, alongside treatment of the PMDD itself.
Why screening matters, in both directions
If PMDD and neurodivergence overlap this often, each clinic should be looking for the other.
- In an ADHD or autism clinic, we ask every woman about her cycle. Does anything change in the fortnight before a period? Does medication seem to stop working? Has there been a pattern since puberty?
- In a GP surgery or gynaecology clinic, a woman with PMDD who also describes lifelong disorganisation, overwhelm, sensory sensitivity or exhaustion from "holding it together" may have ADHD or autism that has never been named.
This matters for treatment. PMDD treated without recognising ADHD often improves only partly. ADHD treated without recognising PMDD can look like medication failing for two weeks in every four. Women in this position are sometimes given other labels first, such as recurrent depression, bipolar disorder or a personality disorder, because nobody put the symptoms on a calendar.
The tool that settles it is simple. A daily symptom diary kept over two cycles, as recommended by the Royal College of Obstetricians and Gynaecologists, shows whether symptoms truly clear after a period or are present all month and worsen before it.
Readiness: the part that is easy to get wrong
Picture a young woman who has finally gone to her GP or a gynaecologist about her periods. She is expecting to talk about hormones. If she is told, in a ten minute appointment, "you may have ADHD and autism", it can land as a shock. She did not come for that. She may hear it as "this is all in your head", or as a judgement on who she is. Some women do not come back.
This is especially true for women who are doing well on paper. They have degrees, careers and families, and they have built their sense of self around coping. A suggestion that they are neurodivergent can feel like an accusation that the coping was never real.
So we believe two things at once. Doctors should think about ADHD and autism when they see PMDD. And the person needs to be ready to hear it. Helping her become ready is part of the doctor's job.
For clinicians: what helps
- Deal with what she came for first. Take the PMDD seriously, start the diary, and offer treatment. Trust comes from being believed.
- Describe patterns before labels. "Many women whose brains are sensitive to hormone changes are also sensitive in other ways, to noise, to stress, to overload. Does that sound familiar?"
- Ask permission. "There is a link between PMDD and some lifelong traits. Would it be helpful to talk about that today, or another time?"
- Offer screening as a choice, not a verdict. A short questionnaire is a way of gathering information. It is not a diagnosis.
- Leave the door open. Give something to read, book a follow up, and let her set the pace. A "not now" is a reasonable answer.
For you, if this has been raised
You do not have to decide anything today. Being screened does not commit you to an assessment, and an assessment does not commit you to a label or to medication. The point of asking is to make sure your treatment fits the whole of you, not only two weeks of the month.
What treatment looks like in the UK
Because the problem is the brain's response to hormone change, treatment works in one of two ways. It either steadies the brain's response or it flattens the hormone swings.
- Steadying the response. SSRI antidepressants are a first line option in the RCOG guideline and in NICE Clinical Knowledge Summaries. They can be taken every day or only in the second half of the cycle. A Cochrane review of 34 trials and 4,563 women found that both approaches probably reduce symptoms, and that daily use is probably somewhat more effective (Jespersen and colleagues, 2024). Cognitive behavioural therapy and regular exercise are also recommended.
- Flattening the swings. Some combined contraceptive pills stop ovulation. Those containing drospirenone may improve PMDD symptoms, though the evidence is of low certainty and the placebo response in trials was large (Ma and Song, Cochrane, 2023). For severe cases, a gynaecologist may offer oestradiol patches with a progestogen, or medication that pauses the ovaries with hormone replacement added back.
No single option suits everyone, and hormonal treatments can worsen mood in some women. Please do not start, stop or change medication without speaking to your prescriber. Your GP is the right first step on the NHS, and can refer to gynaecology or mental health services.
Taking an SSRI only in the difficult window
In depression, an SSRI takes weeks to work. In PMDD it often helps within days, which is one more sign that this is a different condition. That is why an SSRI can be taken only from ovulation until the period starts, in the window when the brain is reacting to the hormone shift. For a woman who is well for the rest of the month, this means fewer tablets and fewer side effects. If there is anxiety or depression all month as well, daily treatment usually makes more sense. It is an option worth raising with your doctor if nobody has mentioned it.
Does the route matter? Tablet, gel, patch, implant or pessary
Yes, and for different reasons with each hormone.
- Oestrogen by tablet passes through the liver first. There it raises clotting proteins. A gel, patch or implant delivers oestradiol through the skin straight into the bloodstream, which avoids that first pass and gives steadier levels. In a UK study of 80,396 women who had a blood clot, HRT tablets were associated with a higher risk of clots, with an odds ratio of 1.58, while gels and patches were not, at 0.93 (Vinogradova and colleagues, BMJ, 2019). For a brain that is sensitive to swings, steadiness is the point, and oestradiol patches or gel with a progestogen are among the options the RCOG lists for severe premenstrual syndrome.
- An implant is the steadiest route of all, and the least flexible. It cannot be switched off quickly if mood worsens, so it is a specialist decision.
- Oral progesterone behaves almost like a different medicine. Swallowed, micronised progesterone is broken down heavily by the gut and liver into allopregnanolone and related substances before it reaches the bloodstream. That is why it makes many women sleepy and is taken at night. Used vaginally, the same capsule largely avoids this first pass (Levine and Watson, 2000), so much less reaches the brain as allopregnanolone.
- For most women that oral effect is calming. In PMDD it can go either way. In a trial of oral progesterone added to oestrogen, mood was worst at middling allopregnanolone levels and better at lower or higher ones (Andréen and colleagues, 2006). A woman who feels worse on oral progesterone may do better on a different dose, the vaginal route, or an intrauterine system.
- Synthetic progestogens are different again. Those in pills, implants and coils are not turned into allopregnanolone in the same way, and their effects on mood vary by type and by person.
The practical point: tell both your psychiatrist and your gynaecologist exactly how you felt on each preparation you have tried, including the route. It is some of the most useful information you can bring.
Saffron: small studies, real interest
Saffron has been tested in a few small trials. In one, 50 women with PMS took saffron 30 mg a day or placebo for two cycles, and symptoms improved more with saffron (Agha-Hosseini and colleagues, BJOG, 2008). In another, 120 women with PMDD took saffron, fluoxetine or placebo in the second half of the cycle. Saffron helped, with fewer side effects than fluoxetine (Rajabi and colleagues, 2020).
These are small, short studies and the findings need repeating. We see saffron as a reasonable thing to discuss for milder symptoms or for women who cannot tolerate an SSRI. It is not a replacement for proven treatment in severe PMDD, and it should not be taken in pregnancy without advice.
If you have ADHD: why the dose may need to change before your period
When oestrogen falls before a period, dopamine activity falls with it, and dopamine is what ADHD medication works through. Many women notice that their ADHD symptoms get worse in that week and that the usual dose seems to do less.
A Dutch clinic reported on nine women with ADHD whose stimulant dose was raised in the premenstrual week. All nine had better attention and mood with few side effects, and all chose to continue (de Jong and colleagues, 2023). Six of the nine also had PMDD. This is a small case series, not a trial, so it is a prompt for a conversation, not a rule. Any change in dose should be planned with your prescriber, with blood pressure, pulse, sleep and appetite monitored. Please do not adjust it yourself.
How we can help at Eton
Most women with this picture have been seen by one specialty at a time. Our psychiatry and gynaecology clinic for women brings both specialties to the same patient, in Harley Street or online across the UK, so you have one plan and not two.
- A full assessment of mood across the cycle, using your diary, so that PMDD, premenstrual worsening of ADHD and all month depression are told apart.
- Assessment for ADHD and autism when you are ready, with clinicians experienced in how both present in women.
- Treatment matched to your cycle, including the timing of an SSRI and, where appropriate, a review of your ADHD dose before your period.
- A gynaecology opinion from Miss Beski on hormonal options, from contraception to HRT, including which route suits you, with both clinicians talking to each other.
- A clear letter to your GP so that care can continue on the NHS where possible.
If this article describes your month, you do not need to wait for another bad fortnight to prove it. Book an appointment with the psychiatry and gynaecology clinic, or read about our women's mental health service.
When to seek help
Seek urgent help if you have thoughts of ending your life or harming yourself, at any point in your cycle. Call 999 or go to A&E if you are in immediate danger. You can call NHS 111 and choose the mental health option, or call Samaritans free on 116 123, at any time. Thoughts that arrive before a period and lift afterwards are still real and still deserve urgent care.
See your GP if your mood changes before your period are affecting work, study or relationships, or if treatment for depression, anxiety or ADHD seems to fail for part of every month. Take a symptom diary if you can.
This article is general information, not medical advice. It cannot replace an assessment by a clinician who knows you.
Where to go next
Summary
- PMDD is not a hormone imbalance. Hormone levels are usually normal, and the brain responds to their normal changes differently.
- With daily symptom tracking, about 1.6% of women in the community meet the full criteria for PMDD, and the risk of suicidal thoughts and attempts is clearly raised.
- PMDD appears about three times more common in women with ADHD. The evidence in autistic women points the same way but is less certain.
- Screening should run in both directions: ask about the cycle in ADHD and autism clinics, and think about neurodivergence when PMDD is seen.
- How and when the question is raised matters. A woman needs to be ready, and helping her get there is part of good care.
- Treatment either steadies the brain's response or flattens the hormone swings. How a hormone is given, by tablet, through the skin or as a pessary, changes its effect, and a two cycle diary guides the choice.
Sources
- Agha-Hosseini, M., Kashani, L., Aleyaseen, A. et al. Crocus sativus L. (saffron) in the treatment of premenstrual syndrome: a double-blind, randomised and placebo-controlled trial. BJOG 115(4), 515–519 (2008). https://doi.org/10.1111/j.1471-0528.2007.01652.x
- Andréen, L., Sundström-Poromaa, I., Bixo, M., Nyberg, S. & Bäckström, T. Allopregnanolone concentration and mood: a bimodal association in postmenopausal women treated with oral progesterone. Psychopharmacology 187(2), 209–221 (2006). https://doi.org/10.1007/s00213-006-0417-0
- Broughton, T., Lambert, E., Wertz, J. & Agnew-Blais, J. Increased risk of provisional premenstrual dysphoric disorder (PMDD) among females with attention-deficit hyperactivity disorder (ADHD): cross-sectional survey study. British Journal of Psychiatry 226(6), 410–417 (2025). https://doi.org/10.1192/bjp.2025.104
- Cherskov, A., Pohl, A., Allison, C., Zhang, H., Payne, R.A. & Baron-Cohen, S. Polycystic ovary syndrome and autism: a test of the prenatal sex steroid theory. Translational Psychiatry 8, 136 (2018). https://doi.org/10.1038/s41398-018-0186-7
- de Jong, M., Wynchank, D.S.M.R., van Andel, E., Beekman, A.T.F. & Kooij, J.J.S. Female-specific pharmacotherapy in ADHD: premenstrual adjustment of psychostimulant dosage. Frontiers in Psychiatry 14, 1306194 (2023). https://doi.org/10.3389/fpsyt.2023.1306194
- Dorani, F., Bijlenga, D., Beekman, A.T.F., van Someren, E.J.W. & Kooij, J.J.S. Prevalence of hormone-related mood disorder symptoms in women with ADHD. Journal of Psychiatric Research 133, 10–15 (2021). https://doi.org/10.1016/j.jpsychires.2020.12.005
- Goldstein, J.M., Jerram, M., Poldrack, R. et al. Hormonal cycle modulates arousal circuitry in women using functional magnetic resonance imaging. Journal of Neuroscience 25(40), 9309–9316 (2005). https://doi.org/10.1523/JNEUROSCI.2239-05.2005
- Groenman, A.P., Torenvliet, C., Radhoe, T.A., Agelink van Rentergem, J.A. & Geurts, H.M. Menstruation and menopause in autistic adults: periods of importance? Autism 26(6), 1563–1572 (2022). https://doi.org/10.1177/13623613211059721
- Groenman, A.P., Welling, L.E. & Pieters, S. The monthly spectrum: premenstrual symptoms across ADHD and autism. Women's Health (2026). https://doi.org/10.1177/17455057261476912
- Hantsoo, L. & Epperson, C.N. Allopregnanolone in premenstrual dysphoric disorder (PMDD): evidence for dysregulated sensitivity to GABA-A receptor modulating neuroactive steroids across the menstrual cycle. Neurobiology of Stress 12, 100213 (2020). https://pmc.ncbi.nlm.nih.gov/articles/PMC7231988
- Henckens, M.J.A.G., van Wingen, G.A., Joëls, M. & Fernández, G. Time-dependent effects of corticosteroids on human amygdala processing. Journal of Neuroscience 30(38), 12725–12732 (2010). https://doi.org/10.1523/JNEUROSCI.3112-10.2010
- Inagaki, T.K., Muscatell, K.A., Irwin, M.R., Cole, S.W. & Eisenberger, N.I. Inflammation selectively enhances amygdala activity to socially threatening images. NeuroImage 59(4), 3222–3226 (2012). https://doi.org/10.1016/j.neuroimage.2011.10.090
- Jespersen, C., Lauritsen, M.P., Frokjaer, V.G. & Schroll, J.B. Selective serotonin reuptake inhibitors for premenstrual syndrome and premenstrual dysphoric disorder. Cochrane Database of Systematic Reviews 8, CD001396 (2024). https://doi.org/10.1002/14651858.CD001396.pub4
- Lever, A.G. & Geurts, H.M. Psychiatric co-occurring symptoms and disorders in young, middle-aged, and older adults with autism spectrum disorder. Journal of Autism and Developmental Disorders 46(6), 1916–1930 (2016). https://doi.org/10.1007/s10803-016-2722-8
- Levine, H. & Watson, N. Comparison of the pharmacokinetics of Crinone 8% administered vaginally versus Prometrium administered orally in postmenopausal women. Fertility and Sterility 73(3), 516–521 (2000). https://doi.org/10.1016/S0015-0282(99)00553-1
- Ma, S. & Song, S.J. Oral contraceptives containing drospirenone for premenstrual syndrome. Cochrane Database of Systematic Reviews 6, CD006586 (2023). https://doi.org/10.1002/14651858.CD006586.pub5
- Martinez, P.E., Rubinow, D.R., Nieman, L.K. et al. 5α-reductase inhibition prevents the luteal phase increase in plasma allopregnanolone levels and mitigates symptoms in women with premenstrual dysphoric disorder. Neuropsychopharmacology 41(4), 1093–1102 (2016). https://doi.org/10.1038/npp.2015.246
- National Institute for Health and Care Excellence. Premenstrual syndrome. Clinical Knowledge Summary. https://cks.nice.org.uk/topics/premenstrual-syndrome/
- Obaydi, H. & Puri, B.K. Prevalence of premenstrual syndrome in autism: a prospective observer-rated study. Journal of International Medical Research 36(2), 268–272 (2008). https://doi.org/10.1177/147323000803600208
- Prasad, D., Wollenhaupt-Aguiar, B., Kidd, K.N., de Azevedo Cardoso, T. & Frey, B.N. Suicidal risk in women with premenstrual syndrome and premenstrual dysphoric disorder: a systematic review and meta-analysis. Journal of Women's Health 30(12), 1693–1707 (2021). https://doi.org/10.1089/jwh.2021.0185
- Rajabi, F., Rahimi, M., Sharbafchizadeh, M.R. & Tarrahi, M.J. Saffron for the management of premenstrual dysphoric disorder: a randomized controlled trial. Advanced Biomedical Research 9, 60 (2020). https://doi.org/10.4103/abr.abr_49_20
- Reilly, T.J., Patel, S., Unachukwu, I.C. et al. The prevalence of premenstrual dysphoric disorder: systematic review and meta-analysis. Journal of Affective Disorders 349, 534–540 (2024). https://doi.org/10.1016/j.jad.2024.01.066
- Royal College of Obstetricians and Gynaecologists. Management of premenstrual syndrome. Green-top Guideline No. 48. BJOG 124(3), e73–e105 (2017). https://doi.org/10.1111/1471-0528.14260
- Schmidt, P.J., Nieman, L.K., Danaceau, M.A., Adams, L.F. & Rubinow, D.R. Differential behavioral effects of gonadal steroids in women with and in those without premenstrual syndrome. New England Journal of Medicine 338(4), 209–216 (1998). https://doi.org/10.1056/NEJM199801223380401
- Sripada, R.K., Marx, C.E., King, A.P. et al. Allopregnanolone elevations following pregnenolone administration are associated with enhanced activation of emotion regulation neurocircuits. Biological Psychiatry 73(11), 1045–1053 (2013). https://doi.org/10.1016/j.biopsych.2012.12.008
- Stiernman, L., Comasco, E., Johansson, M. & Bixo, M. Transcription of GABA-A receptor subunits in circulating monocytes and association to emotional brain function in premenstrual dysphoric disorder. Translational Psychiatry 15, 255 (2025). https://doi.org/10.1038/s41398-025-03465-6
- van Wingen, G.A., van Broekhoven, F., Verkes, R.J. et al. Progesterone selectively increases amygdala reactivity in women. Molecular Psychiatry 13(3), 325–333 (2008). https://doi.org/10.1038/sj.mp.4002030
- van Wingen, G.A., Zylicz, S.A., Pieters, S. et al. Testosterone increases amygdala reactivity in middle-aged women to a young adulthood level. Neuropsychopharmacology 34(3), 539–547 (2009). https://doi.org/10.1038/npp.2008.2
- Vinogradova, Y., Coupland, C. & Hippisley-Cox, J. Use of hormone replacement therapy and risk of venous thromboembolism: nested case-control studies using the QResearch and CPRD databases. BMJ 364, k4810 (2019). https://doi.org/10.1136/bmj.k4810
- The ideas and clinical content of this article are the authors' own, drawn from their clinical practice. AI tools were used to help draft and structure it under the authors' direction, and every claim was checked by the authors before publication.
Frequently Asked Questions
This article was written by Dr. Hossein Rostamipour for Eton Psychiatrists and first published at etonpsychiatrists.co.uk. © 2026 Eton Psychiatrists. All rights reserved.